Electra Therapeutics priced a $350 million Nasdaq IPO, positioning the inflammation-focused biotech to expand its commercial ambitions while continuing development in immune-mediated disease pathways. The offering overshot earlier expectations, adding to a 2026 wave of large biotech listings that has revived IPO appetite for growth-stage companies. The funding arrives as investors appear increasingly willing to underwrite companies with differentiated platform claims and a clear path to clinic-ready assets. In Electra’s case, proceeds are expected to support scaling beyond the research stage into broader development and commercialization readiness. The transaction also underscores how sector sentiment has shifted toward companies offering near-to-medium term asset milestones, particularly where inflammatory biology remains an area of heavy investment. For biopharma professionals watching capital formation, Electra’s IPO adds another datapoint that large, high-cash runway listings are back in the market—an environment that can accelerate M&A, partnerships, and follow-on financing for peer candidates.